Citations

Clear

3942 citation(s) found for "To, Van".

Insights on efficacious doses of PAMORAs for patients on chronic opioid therapy or opioid‐naïve patients
Malderen, Kathleen Van , Halawi, Houssam , Camilleri, Michael , Camilleri, M

Mayo Clinic

Neurogastroenterology & Motility | November 9, 2017 | Volume: 30 | Issue: 5 | Pages: No page available

10.1111/nmo.13250 | PMID 29119706 Get It

AbstractBackgroundOpioid‐induced constipation (OIC) is a major side effect of opioid use. Centrally acting antagonists result in opioid withdrawal or worsening of pain and lead to use of peripherally acting mu‐opioid receptor antagonists (PAMORAs). The required doses of the PAMORAs, methylnaltrexone and naloxegol, in the treatment of OIC are well established in chronic opioid users. OIC may occur after short duration of opioid treatment; the required doses of naloxone, naltrexone, and PAMORAs in opioid‐naïve subjects (with no opioid use for at least 3 months) are unclear. The aim of this review was to evaluate the PAMORA dose required for opioid‐naïve subjects to achieve similar beneficial effects on symptoms or valid surrogates to those observed in chronic opioid users.MethodsA PubMed search of μ‐opioid antagonists to counter μ‐opioid effects included terms: naloxone, naltrexone, methylnaltrexone, alvimopan, and naloxegol, as well as OIC and colonic transit.Key ResultsThe approved dose of methylnaltrexone in chronic opioid users, 0.3 mg/kg subcutaneous (SQ), did not affect motility in opioid‐naïve subjects. Trials investigating the required dose of alvimopan showed 0.5‐1 mg dose was efficacious in treating OIC; a 10‐fold higher dose (12 mg) of alvimopan is needed to block effects of codeine on small bowel and colonic transit in opioid‐naïve subjects compared to chronic opioid users. Opioid‐naïve users need 125 mg of naloxegol to reverse the effects of opioids on transit; this is in contrast to the 12.5 to 25 mg needed to treat OIC in chronic opioid users.Conclusions & InferencesOpioid‐naïve subjects require a higher dose of PAMORA than chronic opioid users to achieve μ‐opioid antagonist effect.
Accumulation of 5-oxoproline in myocardial dysfunction and the protective effects of OPLAH
Pol, Atze van der , Gil, Andrés , Silljé, Herman H.W. , Tromp, Jasper , Ovchinnikova, Ekaterina S. , Vreeswijk‐Baudoin, Inge, Hoes, Martijn F. , Domian, Ibrahim J., Sluis, Bart van de , Deursen, Jan M. van , Veldhuisen, Dirk J. van , Gilst, Wiek H. van , Berezikov, Eugène , Harst, Pim van der , Boer, Rudolf A. de , Bischoff, Rainer , Meer, Peter van der , van der Pol, Atze , van Deursen, Jan M , van Gilst, Wiek H , Berezikov, Eugene , van der Harst, Pim , de Boer, Rudolf A , Bischoff, Rainer , van der Meer, Peter , van de Sluis, Bart , Voors, Adriaan A.

Mayo Clinic

Science Translational Medicine | November 8, 2017 | Volume: 9 | Issue: 415 | Pages: No page available

10.1126/scitranslmed.aam8574 | PMID 29118264 Get It

OPLAH is cardioprotective for myocardial infarction, and its substrate 5-oxoproline is a putative circulating marker for heart failure.
A Cross-sectional Survey of the North American Skull Base Society: Current Practice Patterns of Vestibular Schwannoma Evaluation and Management in North America
Wiet, Richard J., Tombers, Nicole M. , Link, Michael J. , Carlson, Matthew L. , Gompel, Jamie J. Van , Devaiah, Anand K. , Lal, Devyani , Morcos, Jacques J.

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | November 3, 2017 | Volume: 79 | Issue: 03 | Pages: 289-296

10.1055/s-0037-1607319 | PMID 29765827 Get It

Background Very few studies have examined vestibular schwannoma (VS) management trends across centers and between providers. The objective of this study is to examine current practice trends, variance in treatment philosophies, and nuanced or controversial aspects of VS care across North America. Methods This is a cross-sectional survey of North American Skull Base Society (NASBS) members who report regular involvement in VS care. Results A total of 57 completed surveys were returned. Most respondents claimed to have over 20 years of experience and the majority reported working in an academic practice with an affiliated otolaryngology and/or neurosurgery residency program. Sixty-three percent of respondents claimed to evaluate VS patients in clinic with both an otolaryngologist and neurosurgeon involved. Eighty-six percent of respondents claimed to operate on VS with both an otolaryngologist and neurosurgeon involved, while only 18% of neurosurgeons and 9% of otolaryngologists performed surgery alone. There was a wide range in the number of cases evaluated at each center annually. Similarly, there was wide variation in the number of patients treated with microsurgery and radiation at each center. Additional details regarding management preferences for microsurgery, stereotactic radiosurgery, stereotactic radiotherapy, and conservative observation are presented. Conclusion VS management practices vary between providers and centers. Overall, most centers employ a multidisciplinary approach to management with collaboration between otolaryngology and neurosurgery. Overall, survey responses concur with previous studies suggesting a shift toward conservatism in management.
A Cross-sectional Survey of the North American Skull Base Society on Vestibular Schwannoma, Part 2: Perioperative Practice Patterns of Vestibular Schwannoma in North America
Carlson, Matthew L. , Wiet, Richard J., Tombers, Nicole M. , M, Anand Devaiah, Link, Michael J. , Lal, Devyani , Morcos, Jacques J. , Gompel, Jamie J. Van

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | November 3, 2017 | Volume: 79 | Issue: 03 | Pages: 297-301

10.1055/s-0037-1607976 | PMID 29765828 Get It

Introduction Perioperative care of vestibular schwannoma (VS) patients is extremely variable across surgeons and institutions making practice patterns difficult to standardize. No data currently exist detailing this practice variability. Methods The North American Skull Base Society membership was electronically surveyed regarding perioperative care of surgically operated VS patients. Results There were 87 respondents to the survey. Surgical positioning, surgical approach utilized, and perioperative medical adjuncts are quite variable. However, of those performing retrosigmoid approaches, 49% perform this in the supine position, while 33% use a park-bench position with only 2% using the sitting position. In those performing translabyrinthine approaches, 86% perform this in supine position. Although the use of neuromonitoring appears to be standard of care (98%), other than the seventh nerve, there is substantial variability between respondents regarding monitoring of additional cranial nerves. Postoperative antibiotics are used by 65%, postoperative steroids 81%, and postoperative chemical deep vein thrombosis prophylaxis in 68% of survey respondents. Conclusion Although the perioperative adjuncts to VS surgery are variable, there does appear to be a trend in common practice. Therefore, making surgeons aware of these trends may lead to standardized practice or alternatively trials of these variances to instruct which truly improve patient outcomes.
Rates and Locations of Regional Metastases in Sinonasal Malignancies: The Mayo Clinic Experience
Peck, Brandon W., Abel, Kathryn M. Van , Moore, Eric J. , Van Abel, Kathryn M, Van Abel, Kathryn M , Price, Daniel L.

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | November 1, 2017 | Volume: 79 | Issue: 03 | Pages: 282-288

10.1055/s-0037-1607288 | PMID 29765826 Get It

Objectives The objective of this study was to identify factors that may influence the rate and location of regional metastasis in sinonasal malignancies (SNMs). Design This is a retrospective review. Setting This study was set at the single-institution tertiary referral center. Participants A total of 299 patients were treated for SNMs from 1994 to 2014. Main Outcome Measures The main outcome measures were incidence and distribution of regional metastases. Results Several histologic subtypes were treated, with squamous cell carcinoma (28.4%), esthesioneuroblastoma (18.1%), and mucosal melanoma (12.4%) being the most common. Of the 299 patients, 59 (19.7%) developed a regional metastasis, either at presentation or during follow-up. Higher cumulative incidence of regional metastases was significantly associated with histologic type (p ≤0.001) and invasion of the dura (p = 0.005), infratemporal fossa (p = 0.036), orbit (p = 0.020), or palate (p = 0.016). Ipsilateral level II lymph nodes were the most commonly involved nodes. Contralateral regional metastases were associated with higher risk histologic types (p = 0.005) and dural invasion (p = 0.008). Parotid metastases were associated with invasion of the facial soft tissue (p = 0.028), and retropharyngeal metastases were associated with invasion of the pterygoid plates and musculature (p = 0.030). Conclusion Histologic type of SNM appears to be the most important factor in predicting the rate of regional metastases. Histologic type and invasion of certain neighboring structures may help define which lymphatic basins are at highest risk for metastasis.
The limbic and neocortical contribution of α‐synuclein, tau, and amyloid β to disease duration in dementia with Lewy bodies
Ferman, Tanis J. , Aoki, Naoya , Murray, Melissa E. , Graff‐Radford, Neill R. , Gerpen, Jay A. van, Uitti, Ryan J. , Graff‐Radford, Jonathan, Pedraza, Otto , Kantarci, Kejal , Crook, Julia E. , Van Gerpen, Jay A, Kantarci, Kejal , Murray, Melissa E , Ferman, Tanis J , Wszołek, Zbigniew K. , Graff‐Radford, Jonathan , Boeve, Bradley F. , Dickson, Dennis W.

Mayo Clinic

Alzheimer's & Dementia | October 31, 2017 | Volume: 14 | Issue: 3 | Pages: 330-339

10.1016/j.jalz.2017.09.014 | PMID 29100980 Get It

AbstractIntroductionWe sought to assess the individual and combined contribution of limbic and neocortical α‐synuclein, tau, and amyloid β (Aβ) to duration of illness in dementia with Lewy bodies (DLB).MethodsQuantitative digital pathology of limbic and neocortical α‐synuclein, tau, and Aβ was assessed in 49 patients with clinically probable DLB. Regression modeling examined the unique and shared contribution of each pathology to the variance of illness duration.ResultsPatients with diffuse Lewy body disease had more severe pathology of each type and a shorter duration of illness than individuals with transitional Lewy body disease. The three pathologies accounted for 25% of the total variance of duration of illness, with 19% accounted for by α‐synuclein alone or in combination with tau and Aβ. When the diffuse Lewy body disease group was examined separately, α‐synuclein deposition significantly exceeded that of tau and Aβ. In this model, 20% of 24% total variance in the model for duration of illness was accounted for independently by α‐synuclein.DiscussionIn DLB, α‐synuclein is an important predictor of disease duration, both independently and synergistically with tau and Aβ.
Novel GFAP Variant in Adult-onset Alexander Disease With Progressive Ataxia and Palatal Tremor
Gass, Jennifer , Cheema, Anvir, Jackson, Jessica L. , Blackburn, Patrick R. , Gerpen, Jay Van, Gerpen, Jay A. van, Atwal, Paldeep S

Mayo Clinic

The Neurologist | October 31, 2017 | Volume: 22 | Issue: 6 | Pages: 247-248

10.1097/nrl.0000000000000153 | PMID 29095329 Get It

Introduction: Alexander disease is a rare neurodegenerative disease caused by variants in the glial fibrillary acidic protein gene (GFAP). This disorder can develop as an infantile, juvenile or adult-onset form and is characterized by several clinical features, including macrocephaly, seizures, ataxia, and bulbar/pseudobulbar signs. While the majority of these patients have the more progressive infantile form which causes severe leukodystrophy and early death; the less common adult form is more variable (ie, onset age, symptoms), with bulbar dysfunction as the primary feature. Case Report: In our investigation, we describe a patient with progressive neuromuscular issues including dyspnea, dysphagia, dysarthria and progressive ataxia with palatal tremor. Conclusions: Through genetic testing, we determined that our patient has a novel variant in GFAP typical of Alexander disease.
Cognitive impairment in progressive supranuclear palsy is associated with tau burden
Koga, Shunsuke , Parks, Adam , Kasanuki, Koji , Josephs, Keith A. , Ahlskog, J. Eric , Uitti, Ryan J. , Graff‐Radford, Neill R. , Gerpen, Jay A. van, Rademakers, Rosa , Baker, Matthew C, Van Gerpen, Jay A, Koga, Shunsuke , Sánchez-Contreras, Mónica , Baker, Matthew , Wszołek, Zbigniew K. , Dickson, Dennis W.

Mayo Clinic

Movement Disorders | October 30, 2017 | Volume: 32 | Issue: 12 | Pages: 1772-1779

10.1002/mds.27198 | PMID 29082658 Get It

Abstract Background Cognitive impairment is one of the core features of progressive supranuclear palsy. This study aimed to clarify the profile of cognitive impairment and its underlying pathology in progressive supranuclear palsy. Methods We retrospectively reviewed medical records to evaluate the pattern and severity of cognitive impairment in 121 autopsy‐confirmed progressive supranuclear palsy patients. A subset of 37 patients underwent neuropsychological evaluation as part of their clinical workup. The burden of progressive supranuclear palsy‐related tau pathology (neurofibrillary tangles/pretangles, coiled bodies, tufted astrocytes, and threads) was semiquantitatively scored in 20 vulnerable brain regions. Concurrent pathologies potentially associated with cognitive impairment, such as Alzheimer's‐type pathology, were also assessed. To evaluate possible genetic risk factors for cognitive impairment, genetic analysis for APOE and MAPT was performed. Results Ninety patients (74%) had documented cognitive impairment based on neurologic evaluation. In a subgroup with neuropsychological testing (n = 37), executive functioning was the most severely impaired cognitive domain. A global cognitive impairment index (Spearman's rho, −0.49; P = 0.005) and executive functioning were negatively correlated with total tau burden (Spearman's rho, −0.51; P = 0.003), but not correlated with the Alzheimer's‐type pathology. APOE ɛ4 carriers had more severe amyloid pathology, but total tau burden and a global cognitive impairment index did not differ from APOE ɛ4 noncarriers. Conclusion Cognitive impairment in progressive supranuclear palsy, most notably executive dysfunction, is associated with severity of progressive supranuclear palsy‐related tau pathology. © 2017 International Parkinson and Movement Disorder Society